Yeah I'm just not seeing a whole lot of data to support all this attention they're getting. 12 eIND patients. I don't think they've addressed manufacturing as quickly as cydy has.

Lastly but most importantly dr Patterson says he's only seeing gmcsf elevated in 30% of covid patients. And of those elevations a decent number are only slightly elevated above normal with the outliers skewing the mean on the high end.

Dr. P said from get go that il-6 drugs would fail and look what happened to actemra and Kevzara.

Did 11/12 of those eIND patients have elevated gmcsf? Idk.

Does that mean they're pre screening patients for gmcsf elevations for trials? Idk.

Could they have entered trials without knowing the elevation percentages? Yes. Cydy entered into two trials without really knowing that ccl5 was even involved.